Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics - Summary - MDSpire
To assess progression-free survival (PFS) and overall survival (OS) after Lu-177-PSMA treatment according to baseline metastatic timing, Gleason score, and M-stage in patients with mCRPC.
Approach:
Design and population: Retrospective analysis of 344 patients in the FRAMCAP database treated with Lu-177-PSMA in mCRPC treatment lines 1–7; 198 had synchronous and 146 metachronous metastases.
Treatment and outcomes: Patients received PSMA-617 or PSMA-I&T every 4–6 weeks. PFS was measured from treatment initiation to new systemic therapy or death; OS was measured to death from any cause.
Analysis: Kaplan–Meier and Cox regression analyses examined outcomes by metastatic timing, Gleason score (6–7 vs 8–10), and M-stage (M1a, M1b, M1c).
Key Findings:
Median PFS was 12.1 months for synchronous and 13.0 months for metachronous disease; the difference was not statistically significant (p = 0.53).
Median PFS was 12.9 months for Gleason score 6–7 and 11.8 months for score 8–10; the difference was not statistically significant (p = 0.35).
Median PFS by M-stage was 11.9 months for M1a, 9.5 months for M1b, and 8.2 months for M1c; the overall difference was not statistically significant (p = 0.08).
Interpretation:
In the reported PFS analyses, no statistically significant differences were observed by metastatic timing, Gleason score, or M-stage.
Limitations:
The study was retrospective and based on a single-center database.
The provided article context ends during the univariable Cox regression results; OS findings and the remaining regression results are not available.
by Mike Wenzel, Quynh Chi Le, Carolin Siech, Benedikt Hoeh, Konrad Klimek, Christian Happel, Fred Saad, Felix Preisser, Derya Tilki, Markus Graefen, Thomas Steuber, Tobias Maurer, Maximilian C. Kriegmair, Pierre I. Karakiewicz, Felix K. H. Chun, Daniel Groener, Philipp Mandel
